1. Favoriti, P., et al., Worldwide burden of colorectal cancer: a review. Updates Surg, 2016. 68(1): p. 7-11.
2. Edwards, B.K., et al., Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer, 2010. 116(3): p. 544-73.
3. June, C.H., et al., CAR T cell immunotherapy for human cancer. Science, 2018. 359(6382): p. 1361-1365.
4. Tamada, K., et al., Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res, 2012. 18(23): p. 6436-45.
5. Ang, W.X., et al., Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget, 2017. 8(8): p. 13545-13559.
6. Daly, T., et al., Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther, 2000. 7(2): p. 284-91.
7. Pan, Q.Z., et al., Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection. Oncoimmunology, 2020. 9(1): p. 1752563.
8. Morgan, R.A., et al., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther, 2010. 18(4): p. 843-51.
9. Hege, K.M., et al., Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer, 2017. 5: p. 22.
10. Zhang, C., et al., Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA(+) Metastatic Colorectal Cancers. Mol Ther, 2017. 25(5): p. 1248-1258.
11. Thistlethwaite, F.C., et al., The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother, 2017. 66(11): p. 1425-1436.
12. Majzner, R.G. and C.L. Mackall, Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov, 2018. 8(10): p. 1219-1226.
13. Lu, Y. and J.R. Swartz, Functional properties of flagellin as a stimulator of innate immunity. Sci Rep, 2016. 6: p. 18379.
14. Luchner, M., S. Reinke, and A. Milicic, TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases. Pharmaceutics, 2021. 13(2).
15. Mett, V., et al., A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications. Commun Biol, 2021. 4(1): p. 466.
16. Lim, J.S., et al., Flagellin-dependent TLR5/caveolin-1 as a promising immune activator in immunosenescence. Aging Cell, 2015. 14(5): p. 907-15.
17. Yang, H., et al., The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget, 2016. 7(3): p. 2936-50.
18. Mizel, S.B. and J.T. Bates, Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol, 2010. 185(10): p. 5677-82.
19. Hajam, I.A., et al., Bacterial flagellin-a potent immunomodulatory agent. Exp Mol Med, 2017. 49(9): p. e373.
20. Nguyen, C.T., et al., Flagellin enhances tumor-specific CD8(+) T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. Vaccine, 2013. 31(37): p. 3879-87.
21. Rhee, S.H., E. Im, and C. Pothoulakis, Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology, 2008. 135(2): p. 518-28.
22. Mett, V., et al., Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene, 2018. 37(4): p. 439-449.
23. Jahanafrooz, Z., et al., Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment. J Cell Physiol, 2020. 235(5): p. 4153-4166.
24. Eun, K., S.W. Ham, and H. Kim, Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. BMB Rep, 2017. 50(3): p. 117-125.
25. Ricci-Vitiani, L., et al., Identification and expansion of human colon-cancer-initiating cells. Nature, 2007. 445(7123): p. 111-5.
26. Todaro, M., et al., Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell, 2007. 1(4): p. 389-402.
27. Dai, H., et al., Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology, 2020. 9(1): p. 1846926.
28. Wang, Y., et al., CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. Oncoimmunology, 2018. 7(7): p. e1440169.
29. Rezvani, K., et al., Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther, 2017. 25(8): p. 1769-1781.
30. Muller, N., et al., Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1alpha-secreting Glioblastoma. J Immunother, 2015. 38(5): p. 197-210.
31. Yu, M., et al., Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma. Mol Ther, 2018. 26(2): p. 366-378.
32. Han, J., et al., CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Sci Rep, 2015. 5: p. 11483.
33. Chu, J., et al., CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia, 2014. 28(4): p. 917-27.
34. Schonfeld, K., et al., Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther, 2015. 23(2): p. 330-8.
35. Wang, X., et al., The prognostic value of combining CD133 and mismatch repair proteins in patients with colorectal cancer. Clin Exp Pharmacol Physiol, 2020.
36. Vera, J., et al., T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood, 2006. 108(12): p. 3890-7.
37. Wang, Y., et al., Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumor potential via epigenetic reprogramming. Nat Commun, 2021. 12(1): p. 409.
38. Burdelya, L.G., et al., An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science, 2008. 320(5873): p. 226-30.
39. Wang, C.M., et al., Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. Clin Cancer Res, 2017. 23(5): p. 1156-1166.
40. Feng, K.C., et al., Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol, 2017. 10(1): p. 4.
41. Ao, X., et al., Anti-alphaFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against alphaFR-positive Ovarian Cancer. J Immunother, 2019. 42(8): p. 284-296.
42. Jureczek, J., et al., An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells. Sci Rep, 2019. 9(1): p. 10547.
43. Kaczanowska, S. and E. Davila, Ameliorating the tumor microenvironment for antitumor responses through TLR5 ligand-secreting T cells. Oncoimmunology, 2016. 5(4): p. e1076609.
44. Krivokrysenko, V.I., et al., Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharmacol Exp Ther, 2012. 343(2): p. 497-508.
45. Eremina, N.V., et al., First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients. Oncotarget, 2020. 11(14): p. 1273-1288.
46. Jiang, Q., et al., Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev, 2005. 16(4-5): p. 513-33.
47. Michaud, A., et al., IL-7 enhances survival of human CD56bright NK cells. J Immunother, 2010. 33(4): p. 382-90.
48. Cai, Z., et al., Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res, 2011. 71(7): p. 2466-75.
49. Brackett, C.M., et al., Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc Natl Acad Sci U S A, 2016. 113(7): p. E874-83.
50. Means, T.K., et al., The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol, 2003. 170(10): p. 5165-75.
51. Kaczanowska, S., A.M. Joseph, and E. Davila, TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol, 2013. 93(6): p. 847-63.
52. Burdelya, L.G., et al., Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci U S A, 2013. 110(20): p. E1857-66.
53. Blander, J.M. and R. Medzhitov, Regulation of phagosome maturation by signals from toll-like receptors. Science, 2004. 304(5673): p. 1014-8.
54. Miao, E.A., et al., Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol, 2006. 7(6): p. 569-75.
55. Lightfield, K.L., et al., Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin. Nat Immunol, 2008. 9(10): p. 1171-8.